首页> 外文期刊>Clinical, Cosmetic and Investigational Dermatology >A series of in vitro and human studies of a novel lip cream formulation for protecting against environmental triggers of recurrent herpes labialis
【24h】

A series of in vitro and human studies of a novel lip cream formulation for protecting against environmental triggers of recurrent herpes labialis

机译:新型唇霜配方的一系列体外和人体研究,可防止唇疱疹反复发作的环境诱因

获取原文
       

摘要

Purpose: These studies describe the testing of a novel, daily-use lip cream designed for individuals with lips prone to recurrent herpes labialis (RHL) that protects against environmental triggers. Subjects and methods: In vitro occlusive and in vitro and in vivo photoprotection analyses, a characterization of normal vs dry lips, and a randomized, evaluator-blinded, clinical trial that assessed the lip cream in healthy subjects with dry lips were conducted. In the clinical trial, subjects applied the lip cream or were untreated and evaluated using transepidermal water loss (TEWL), corneometry, visual assessments of lip dryness, expert photographic evaluations, and subject-rated outcomes. Results: The lip cream’s in vitro water vapor transmission rate (84.1 g/(msup2/sup h)) indicated moderate occlusivity. The lip cream, but not placebo or control (water), reduced ultraviolet A (UVA)- and UVB-induced DNA damage, and tumor necrosis factor-α (EpiDermsupFT/sup) and prostaglandin E2 release (EpiDermsupFT/sup and EpiGingival?). The lip cream’s in vivo sun protection factor (SPF) was 12.2 (lower confidence limit, 11.3) and SPF/UVA protection factor ratio was 0.9. The characterization of dry vs normal lips identified differences in moisturization. In the clinical trial, the lip cream significantly decreased TEWL (difference: –7.19 [95% CI: ?11.41, –2.98]; P 0.01), increased corneometry (difference: 4.62 [95% CI: 1.05, 8.19]; P 0.05), and reduced visual dryness (difference: –1.48 [95% CI: 2.24, –0.71]; P 0.001) compared to untreated subjects. Significant benefits were also observed on expert photographic assessments of scaling (difference: –0.89 [95% CI: ?1.75, –0.03]; P 0.05), cupping (difference: –1.50 [95% CI: ?2.30, –0.70]; P 0.001), and healthy appearance (difference: –1.44 [95% CI: ?2.29, –0.58]; P 0.01); differences in overall healthy appearance were not significant ( P =0.51). Subject-rated assessments indicated improvements in cracking, dryness, and flaking in the lip cream group but worsening in untreated subjects. Conclusion: These studies indicate that this novel, daily-use lip cream protects against UV radiation, drying, and chapping, which are established environmental RHL triggers.
机译:目的:这些研究描述了一种新型的日常使用的润唇膏的测试,该润唇膏是为嘴唇易复发的唇唇疱疹(RHL)的个人设计的,可防止环境诱因。受试者和方法:进行了体外闭塞,体外和体内的光保护分析,正常唇和干唇的表征以及进行了评估者双盲的随机临床试验,该试验评估了干唇健康受试者的润唇膏。在临床试验中,受试者使用了润唇膏或未经治疗,并使用了表皮失水(TEWL),角质测量,嘴唇干燥的视觉评估,专业的摄影评估和受试者评估的结局。结果:唇霜的体外水蒸气透过率(84.1 g /(m 2 h))表明具有中等的咬合性。护唇霜可减轻紫外线A(UVA)和UVB诱导的DNA损伤以及肿瘤坏死因子-α(EpiDerm FT )和前列腺素E2释放(EpiDerm),但不能降低安慰剂或对照(水) FT 和EpiGingival?)。润唇膏的体内防晒系数(SPF)为12.2(较低的置信度为11.3),SPF / UVA防护系数之比为0.9。嘴唇干燥与正常嘴唇的特征确定了保湿的差异。在临床试验中,润唇膏显着降低了TEWL(差异:–7.19 [95%CI:?11.41,–2.98]; P <0.01),角质测定值升高(差异:4.62 [95%CI:1.05、8.19]; P与未治疗的受试者相比,<0.05),视觉干燥度降低(差异:–1.48 [95%CI:2.24,–0.71]; P <0.001)。在缩放比例的专家摄影评估中也观察到了显着的好处(差异:–0.89 [95%CI:?1.75,–0.03]; P <0.05),拔罐(差异:–1.50 [95%CI:?2.30,–0.70] ; P <0.001)和健康的外观(差异:–1.44 [95%CI:?2.29,–0.58]; P <0.01);整体健康外观的差异不显着(P = 0.51)。受试者评估的评估表明,润唇膏组的龟裂,干燥和剥落有所改善,但未经治疗的受试者恶化了。结论:这些研究表明,这种新颖的日用润唇膏可防止紫外线辐射,干燥和裂,这是环境RHL触发因素。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号